These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 26538618

  • 1. Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.
    Zhang M, Gulotta B, Thomas A, Kaley T, Karimi S, Gavrilovic I, Woo KM, Zhang Z, Arevalo-Perez J, Holodny AI, Rosenblum M, Young RJ.
    Neuro Oncol; 2016 May; 18(5):735-43. PubMed ID: 26538618
    [Abstract] [Full Text] [Related]

  • 2. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F, Guzzardi G, Del Sette B, Sponghini AP, Matheoud R, Soligo E, Trisoglio A, Carriero A, Stecco A.
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.
    Ellingson BM, Cloughesy TF, Lai A, Mischel PS, Nghiemphu PL, Lalezari S, Schmainda KM, Pope WB.
    Neuro Oncol; 2011 Oct; 13(10):1151-61. PubMed ID: 21856685
    [Abstract] [Full Text] [Related]

  • 5. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.
    Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J.
    Radiology; 2009 Jul; 252(1):182-9. PubMed ID: 19561256
    [Abstract] [Full Text] [Related]

  • 6. Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.
    Patel KS, Everson RG, Yao J, Raymond C, Goldman J, Schlossman J, Tsung J, Tan C, Pope WB, Ji MS, Nguyen NT, Lai A, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM.
    Neurosurgery; 2020 Oct 15; 87(5):931-938. PubMed ID: 32365185
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
    Wen Q, Jalilian L, Lupo JM, Molinaro AM, Chang SM, Clarke J, Prados M, Nelson SJ.
    J Neurooncol; 2015 Jan 15; 121(2):331-9. PubMed ID: 25351579
    [Abstract] [Full Text] [Related]

  • 9. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.
    Ellingson BM, Sahebjam S, Kim HJ, Pope WB, Harris RJ, Woodworth DC, Lai A, Nghiemphu PL, Mason WP, Cloughesy TF.
    AJNR Am J Neuroradiol; 2014 Apr 15; 35(4):673-9. PubMed ID: 24136647
    [Abstract] [Full Text] [Related]

  • 10. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study.
    Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, Barboriak D, Abrey LE, Mikkelsen T, Jain R, Paleologos NA, Lada P, Prados M, Goldin J, Wen PY, Cloughesy T.
    J Neurooncol; 2012 Jul 15; 108(3):491-8. PubMed ID: 22426926
    [Abstract] [Full Text] [Related]

  • 11. Enhancing tumor apparent diffusion coefficient histogram skewness stratifies the postoperative survival in recurrent glioblastoma multiforme patients undergoing salvage surgery.
    Zolal A, Juratli TA, Linn J, Podlesek D, Sitoci Ficici KH, Kitzler HH, Schackert G, Sobottka SB, Rieger B, Krex D.
    J Neurooncol; 2016 May 15; 127(3):551-7. PubMed ID: 26830088
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.
    Boxerman JL, Zhang Z, Safriel Y, Rogg JM, Wolf RL, Mohan S, Marques H, Sorensen AG, Gilbert MR, Barboriak DP.
    Neuro Oncol; 2018 Sep 03; 20(10):1400-1410. PubMed ID: 29590461
    [Abstract] [Full Text] [Related]

  • 14. Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.
    McDonald CR, Delfanti RL, Krishnan AP, Leyden KM, Hattangadi-Gluth JA, Seibert TM, Karunamuni R, Elbe P, Kuperman JM, Bartsch H, Piccioni DE, White NS, Dale AM, Farid N.
    Neuro Oncol; 2016 Nov 03; 18(11):1579-1590. PubMed ID: 27106406
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
    Burth S, Kickingereder P, Eidel O, Tichy D, Bonekamp D, Weberling L, Wick A, Löw S, Hertenstein A, Nowosielski M, Schlemmer HP, Wick W, Bendszus M, Radbruch A.
    Neuro Oncol; 2016 Dec 03; 18(12):1673-1679. PubMed ID: 27298312
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.